Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TLRY
Tilray Brands, Inc. (TLRY) EV/Sales
As of 16 October 2026, Tilray Brands, Inc. (TLRY) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.0× (September 2017) to 526× (September 2018); the current reading is higher than 9% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.8× | 60.15% |
| FY2025 | 0.5× | (71.77%) |
| FY2024 | 1.8× | (31.43%) |
| FY2023 | 2.7× | 45.47% |
| FY2023 | 1.8× | (39.91%) |
| FY2022 | 3.0× | (17.94%) |
| FY2022 | 3.7× | (32.88%) |
| FY2021 | 5.5× | (43.11%) |
| FY2021 | 9.7× | (71.32%) |
| FY2020 | 33.9× | 373.53% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 0.8× | (7.00%) |
| May 2026 | 0.8× | (20.63%) |
| Feb 2026 | 1.0× | (0.23%) |
| Nov 2025 | 1.0× | (33.66%) |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.8× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)